Leprosy Clinical Trial - Efficacy & Tolerability of Adjunct Metformin for

Status Recruiting

Clinical Trial Summary

This trial aims to evaluate the efficacy, tolerability and safety of adjunct metformin added to standard-of-care multi-drug therapy (MDT) in patients with multibacillary leprosy, and explore its effects on immunological endpoints. A double-blind, placebo controlled proof-of-concept trial will be performed in which patients with newly diagnosed multibacillary leprosy will be randomized (1:1) to metformin 1000mg OD versus placebo for 24 weeks in addition to MDT during 48 weeks. The main research question is whether adjunctive metformin, combined with MDT, will improve the clinical outcomes of patients with multibacillary leprosy by mitigating leprosy reactions, thereby reducing nerve damage and corticosteroid use and its associated morbidity. The second aim is to explore whether adjunct metformin, added to MDT, has an acceptable tolerability and safety in patients with multibacillary leprosy.

Clinical Trial Description

A double-blind, placebo-controlled randomized proof-of-concept Phase 2 trial will be performed evaluating the efficacy, safety and tolerability of adjunct metformin combined with standard of care MDT to mitigate leprosy reactions. Patients with newly diagnosed multibacillary leprosy will be randomized (1:1) to metformin 1000mg OD versus placebo for 24 weeks in addition to MDT during 48 weeks. The trial aims to enroll 166 patients, aged between 18-65 years old, in leprosy endemic areas in Indonesia. Primary endpoints are the proportion of participants experiencing a leprosy reaction during the full duration of the study and the proportion of participants with at least one adverse event within the first 28 weeks of the study. Secondary endpoints are the severity and time to first leprosy reaction, the number of leprosy reactions, the cumulative corticosteroid usage, and quality of life. The total study follow-up is 48 weeks. This METLEP trial is financially supported by the Leprosy Research Initiative (grant number: FP20\4). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05243654
Study type	Interventional
Source	Eijkman Oxford Clinical Research Unit, Indonesia
Contact	Marlous Grijsen, MD, PhD
Phone	62-21-31900971
Email	mgrijsen@eocru.org
Status	Recruiting
Phase	Phase 2
Start date	October 1, 2022
Completion date	February 28, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03302897` - Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers	Phase 1
Completed	`NCT05091216` - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients	N/A
Completed	`NCT00860717` - The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients	N/A
Recruiting	`NCT06222372` - Novel Interventions and Diagnostic Tests for Leprosy	N/A
Terminated	`NCT03084614` - CD8 Reactivity to Microorganisms in Blood and Breast Milk
Recruiting	`NCT05597280` - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy	Phase 3
Terminated	`NCT01751503` - Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer	N/A
Active, not recruiting	`NCT03324035` - Treatment of Neuropathic Pain in Leprosy	Phase 3
Recruiting	`NCT03683745` - Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Recruiting	`NCT02550080` - Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome	Phase 4
Completed	`NCT02484469` - Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial	N/A
Completed	`NCT01165840` - Effect of Weight and/or Obesity on Dapsone Drug Concentrations	Phase 4
Completed	`NCT00919542` - Ciclosporin in the Management of New Erythema Nodosum Leprosum	Phase 2
Completed	`NCT05406479` - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)	Phase 2
Recruiting	`NCT03807362` - CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum	Phase 2
Completed	`NCT01006759` - Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients	Phase 1
Completed	`NCT03662022` - Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar	Phase 3
Completed	`NCT01920750` - Leprosy Skin Test Antigens Phase 1	Phase 1
Not yet recruiting	`NCT03947437` - Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients	Phase 1/Phase 2
Completed	`NCT00669643` - Uniform Multidrug Therapy Regimen for Leprosy Patients	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy — MetLep

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms